HIV Patients sue Gilead, saying drug company intentionally delayed safer HIV medicine. Kidney Damage and Broken Bones for HIV Positive Patients: Caused By Drug Company Greed
The Lombardo Law Firm is filing lawsuits on behalf of people who took one or more of Gilead’s TDF drugs—Truvada, Viread, Atripla, Complera, and Stribild—and may have suffered kidney disease and/or bone density loss. Gilead is accused of knowingly promoting and selling drugs that could cause serious side effects. Gilead is accused of allegedly withholding a safer version of the medication (TAF drugs) You or someone you love may be eligible for compensation for your injuries, please contact the Lombardo Law Firm for a free consultation at 909-482-0384 Call now to learn about your rights.
Gilead Sciences, Inc. is a pharmaceutical company best known for making and selling the HIV treatment and prevention drugs. While these drugs can be effective and helpful for HIV-positive patients and as a preventive measure, new information is coming to light suggesting that two major side-effects: Kidney Damage and Loss of Bone Mineral Density, are risks that could and should have been avoided.
If you or someone you care for has taken one or more of the HIV/AIDS drugs Truvada, Atripla, Complera, Viread, or Stribild, you may have an unnecessary increased risk of permanent or fatal damage to your kidneys and/or bones. This risk, although well known and discussed, may be due to drug company fraud and potentially could have been avoided. The active ingredient in Truvada, Atripla, Complera, Viread, and Stribild is tenofovir disoproxil fumarate (“TDF”). Gilead has known since the 1990s that this drug, TDF, had toxic effects on the kidney and bones of patients who would take it. At the same time Gilead was developing TDF in the 1990s, it was also working on TAF, a slightly different form of the drug. TAF is much more potent and effective than TDF and because of its potency, TAF can be given in a lower dose…which exposes the kidneys and bones to less of the toxic effects.